Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (January 2015)

38 slides from Sorrento Therapeutics's investor presentation, Jan 12, 2015

  1. Slide 1: Next-Generation Cancer Therapeutics

    Slide 1: Next-Generation Cancer Therapeutics

    Exhibit 99.2 Exhibit 99.2 Next-Generation January 2015 Cancer Therapeutics

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor This regarding “believe,” Actual Company candidates, available other 2filings presentation factors with results to our may “estimate” including the Statement affecting business, may not Securities Company contains proceed differ and timelines, such NASDAQ: technologies from “continue” as

  3. Slide 3: A Comprehensive Cancer Company

    Slide 3: A Comprehensive Cancer Company

    A Comprehensive Deep Novel Small Molecules Cytotoxics CYNVILOQ™ Bispecific Cancer Targeted MYC 3CYNVILOQ, and inhibitor Biologics breakthrough Pain Therapy Complementary Abs Therapy Immunotherapy CAR.TNK, Intractable Anti-VEGR2 PD-1, Cell Targeted Oncology Care combination Supportive PD-L1, CAR.TNK

  4. Slide 4: Corporate Pipeline Events

    Slide 4: Corporate Pipeline Events

    Corporate Pipeline cellular Tumor-attacking “The Immunotherapy Company” Antibody Pilot CYNVILOQ Licensing Pharmaceutical Exclusive 4conjugates PK First immunotherapy Unlocking data global agreement research Events joint (ADCs) autoimmune albumin-bound from for venture Soon-Shiong, NeuKoplast) partne

  5. Slide 5: Pipeline by indication and phase

    Slide 5: Pipeline by indication and phase

    Deep Intractable Significant INDICATION Metastatic CYNVILOQ™ RTX G-MAB Bi-Specific PD-L1.TNK, ADC MYC *Abraxane® 5PDL1.TNK, VEGFR2, and Inhibitor Immuno-oncology Complementary Breast Opportunities Ab CD123.TNK, (paclitaxel CD123.TNK, >PD-L1/c-MET; Solid Non-Small c-MET, Cancer TARGET Cancer tumors P

  6. Slide 6: Lead Oncology Product: Cynviloq

    Slide 6: Lead Oncology Product: Cynviloq

    Lead Oncology Cynviloq 6Registration (Paclitaxel Trial Product polymeric Opportunity micelle)

  7. Slide 7: Cynviloq: Next Generation Paclitaxel

    Slide 7: Cynviloq: Next Generation Paclitaxel

    Cynviloq: Maximum Generation 1st castor Biological 2nd 3rd paclitaxel ~25 polymeric diblock 7*Celgene Taxol® Cynviloq Albumin-bound nmoilcopolymer polyethylene Presentation Polyoxyethylated 130 Mean Next micelle polymer: Peak Cremophor Formulation Chemical nmGeneration size serum newMean Poly-lactid

  8. Slide 8: Cynviloq Clinical Trials Summary

    Slide 8: Cynviloq Clinical Trials Summary

    Cynviloq Total Trials >300 Possible 230 260 MBC Phase with PM-Safety: Efficacy 8Datamg/m2 Cremophor on number mg/m2 in established 1:file; 2: 2b*: 2*: 3: S. Phase (total Completed GPMBC301. and Clinical 1st Korea Chemo-naïve + Completed *safety (q3w) line of cis carbo n=80) Investigator 3patients EL

  9. Slide 9: Comparative Response Rate

    Slide 9: Comparative Response Rate

    Comparative Rate Response *Overall ** 9*** Trieu Gradishar Guan (%)et al. et al. 2013. Phase et 2007. al. 2005. IG-001 3 MBC ASCO J Clin for Clinical Annual Metastatic Oncol, Results Meeting 23:7794-7803. Breast Proceedings Cancer- Interim Part I. Analysis Jun 20;25of(Suppl a Phase 18):1038. 3 Trial

  10. Slide 10: Pilot PK Data Assessment

    Slide 10: Pilot PK Data Assessment

    PilotAssessment Log-linear BE Ratio Parameters Ln(AUC0 (%) Ln(Cmax Point 110—Ln(AUC0 10 vs. PK estimate ofAlbumin-Bound Cynviloq/ Data )to Plot Albumin-bound 102.5 ) Analyses 109.1 N(n=8) and to =83.10 53 )Sample 93.98 with –Suggest Paclitaxel 126.35 –90% paclitaxel Size 126.58 power Estimate 90% CI

  11. Slide 11: Bioequivalence Study Design (TRIBECA)

    Slide 11: Bioequivalence Study Design (TRIBECA)

    Bioequivalence -(TRIal Key (n Duration: Albumin-bound Cycle paclitaxel (90% Note: Cynviloq T 11Patients R= I27)* Parameters: B CI) Previous 1establishing 2 E paclitaxel Cynviloq historical Infusion with 3C Endpoints: weeks A™MBC trial =crossover Cynviloq (TRIal Accelerated Dose: time: +BioEquivalenc

  12. Slide 12: TRIBECA Enrollment Status

    Slide 12: TRIBECA Enrollment Status

    TRIBECA 20 consistent Active Enrollment 12 Sites sitesEnrolled Sites (East with Patient 54 and Europe, pts historical Patient Patients Enrollment USA, Enrollment nab-paclitaxel Asia) On Track actively toxicity recruiting profile patients Target 54 MBC patients to establish BE exceeded in Dec 2014 Re

  13. Slide 13: Estimated First Product Timeline

    Slide 13: Estimated First Product Timeline

    Estimated First Product BE NDA Approval FDA 2016 LAUNCH *Estimates, 2014 2015 Study 13 Filing patient filing: launch 2016 Timeline subject dosed: Q3(MBC 2015March to anddiscussions and Next 31, NSCLC): Steps* 2014with Last 2016 the patient FDA.in: January 2015

  14. Slide 14: Resiniferatoxin (RTX) for Intractable Cancer Pain

    Slide 14: Resiniferatoxin (RTX) for Intractable Cancer Pain

    Resiniferatoxin RTX Intractable 14 Pain Cancer (RTX): A Novel, Non-opiate Analgesic

  15. Slide 15: Two Products for Intraganglionic or Intrathecal Use

    Slide 15: Two Products for Intraganglionic or Intrathecal Use

    Two the Intraganglionic: near Dorsal Cross spinal TRPV1-positive (dark Absence positive 15 treatment Injection Products brown) Sections cord* root cells dorsal of TRPV1- ganglion after for Sites root ofinjection cells Human RTX ganglion = Use intocerebrospinal or Intrathecal:fluid injection space in

  16. Slide 16: Interim Phase 1/2 Trial Data

    Slide 16: Interim Phase 1/2 Trial Data

    Summary Sponsored 6DESIGN (49-61 No toxicities injection Clinically explored improvement 16 RESULTS advanced unexpected years; injection complete OVERVIEW of meaningful Trial cancer Interim 4inAll M/ QOL(n=2) patients 2F, 6relief Data patients increased Improved MBC, optimization post- from with had

  17. Slide 17: Next Steps for RTX Development

    Slide 17: Next Steps for RTX Development

    Next Complete trial n=45-60 OBJECTIVES 2015 for Phase End ~3 17 years (intrathecal ofSteps and 1/2 Phase patients; for 2016 trial(s) intractable for clinical 2RTX End Initiate meeting injection (intraganglionic optimization of Development development cancer Phase Phase with ) under pain 2FDA 3 meeti

  18. Slide 18: Immunotherapy: G-MAB, Conjugation, Neukoplast

    Slide 18: Immunotherapy: G-MAB, Conjugation, Neukoplast

    Immunotherapy G-MAB + Conjugation 18NeukoplastChemistries Proprietary Toxins Programs &

  19. Slide 19: G-MAB: Very Diverse Proprietary Library

    Slide 19: G-MAB: Very Diverse Proprietary Library

    G-MAB: Very Proprietary RNA Freedom-To-Operate generation (over No Difficult Small High Immune Most G Size 19Protein-Coupled stacking of high Value amplification Difficult 70 Peptides Target modulation: targets Targets: Library library technology: Oncology royalties Antigen Targets: screened) divers

  20. Slide 20: Anti-PD-L1 Exhibits Potent Immune Activity

    Slide 20: Anti-PD-L1 Exhibits Potent Immune Activity

    Anti-PD-L1 T Sorrento mAb IL-2 Day Tumor *** mAbs xenograft p<0.05, 20Cell Model** Mouse (pg/mL) mAb @ Activation Growth mean Competitor 0.05 model mAb Modulation* tumor mg/mL Inhibition using (%) Exhibits volumes IFN-g H1975 (%) Potent (pg/mL) are human significantly Activity Immune NSCLC cells; re

  21. Slide 21: Anti-PD1 Immune Activation

    Slide 21: Anti-PD1 Immune Activation

    Anti-PD1 Immune Activation (%) C — H T PD1 Competitor Sorrento 21ell uman 2 IFN PD1Cyno Modulation* mAb IL CTLA-4 mAb gmAb (pg/mL) Human Sorrento Exhibits Control CD28 (pg/mL) Human Target mAb Excellent ICOSSpecificity Human control Activity PBS

  22. Slide 22: Proprietary Conjugation Chemistries

    Slide 22: Proprietary Conjugation Chemistries

    Proprietary Chemistries Maleimide K-Lock Destabilizes C-Lock Enhances 22 conjugation ADC conjugation K-Lock Enable antibody stability Homogeneous andstructure C-Lock Prolongs Drug-antibody Conjugation PK ADCs profile Reduces linkage off-target not stableeffects Altered PK profile Off-target drug eff

  23. Slide 23: Proprietary Toxins Show High Potency

    Slide 23: Proprietary Toxins Show High Potency

    Proprietary EC50 SBKR3 HCC1954 BT474 MDA-MB-361 ZR75 HCC1419 MDA-MB-453 MDA-MB-175 N87 OE-19 SKOV-3 Trastuzumab 23 Gastric (pM) Breast Gastric Breast Breast Ovarian Breast High Cancer +++ +++ was +++ +++ +++ Breast Potency 368 +++ used 215 818 Her-2 176 95139 298 124 391 +++ ++ + 150 as 72 126 164 >

  24. Slide 24: In Vivo Proof-of-Concept of Sorrento ADCs

    Slide 24: In Vivo Proof-of-Concept of Sorrento ADCs

    In Vivo VEGFR2-ADC c-MET-ADC A431 U87 24 xenograft; squamous-cell Proof-of-Concept STI-D0602 dosing STI-D0168 carcinoma twice of Sorrento weekly; cells; maytansinoid ^indicates ADCs dosing drug conjugates

  25. Slide 25: The Immunotherapy Company Joint Venture

    Slide 25: The Immunotherapy Company Joint Venture

    “The companies Independent Both Joint 25 venture Immunotherapy company willwill drawcontribute Antibody focused from NantWorks’ on to JVadvancing its Company” pipeline proteomic next of clinical generation and genomic and preclinical immunotherapies capabilities assetsand of against novel Sorrento’s

  26. Slide 26: An Exclusive Joint Partnership

    Slide 26: An Exclusive Joint Partnership

    AN EXCLUSIVE CAR.TNK 26 is a trademark JOINT PARTNERSHIP owned by Sorrento Therapeutics, Inc. Neukoplast is a trademark owned by Conkwest, Inc.

  27. Slide 27: Advancing Beyond Neukoplast

    Slide 27: Advancing Beyond Neukoplast

    Advancing Beyond Neukoplast® (“off-the-shelf”) Proprietary Broad solid ‘GMP No over 27 clinical 40 and anti-cancer inpatients CAR-T aliquid Box’ Cellular DLTs/SAEs gene NKtumors Cell production treated library insertion cell activity Immunotherapy Therapies line (over FTO in in Proprietary Vast High

  28. Slide 28: CAR.TNK Key Differentiators

    Slide 28: CAR.TNK Key Differentiators

    CAR.TNK Simple: Cell Transduction characteristics Broad: MOA mechanisms Good: Safety IL-6 encephalitis; COGS manufacturing 28 Production production killing On-target limited Low: Multiple Off-the-shelf vs(“off-target CAR-T large Death through 100%: CAR-T: due of for CAR-modified Cardiotoxicity; MOAs

  29. Slide 29: Unmodified Neukoplast Phase 1 Studies

    Slide 29: Unmodified Neukoplast Phase 1 Studies

    Unmodified Phase More Advanced Many Promising No 29 DLTs; than 1 Studies patients only metastatic activity 40Neukoplast patients received 1 “grade against disease treated multiple 4Clinically SAE” different refractory dosing (hypoglycemia Validated cancer to regimens chemo, types, In Several likely

  30. Slide 30: Neukoplast Mixed Lymphocyte Reaction Assay

    Slide 30: Neukoplast Mixed Lymphocyte Reaction Assay

    Neukoplast T Mixed Gold: 35000 CPM 20000 25000 130000 0-D 5000 Lymphocytes Co-cultured 30 5000 0000 cell 15000 Donor Proliferation PHA Aqua: Lymphocyte Allogeneic do with 1Donor from notNeukoplast stimulate 2measured Reaction 2healthy Donorallogeneic donors (7 (MLR) using Neukoplast days)co-cultured

  31. Slide 31: CAR.TNK: Clonal and Titratable

    Slide 31: CAR.TNK: Clonal and Titratable

    CAR.TNK: Clonal Multiple Engages Titratable: 31 cell the killing repeat lines CAR-modified adaptive mechanisms—CAR-targeted expressing dosing immune option; Neukoplast onesystem or controllable more through CARs dose as cytokine towell establish exposure as secretion broad atorange intrinsic manage

  32. Slide 32: Serial Killing and Homing of Her2.TNK

    Slide 32: Serial Killing and Homing of Her2.TNK

    Serial IN Homing Inhibition Growth “Serial Selective Schoenfeld 32 VIVOKilling killing” inhibition tocytotoxicity PRECLINICAL ofHer2 etHer2+ of al.ofHer2+ expressing Mol Her2+ and RCC Therapy, (spares killing Cells target metastasis MOUSE tumors by correlate normal in cells Her2.TNK press DATA even

  33. Slide 33: Her2.TNK Mechanism of Action

    Slide 33: Her2.TNK Mechanism of Action

    Her2.TNK Her2+ Schoenfeld 33 Cancer In et Action: al. Cells Mol Targeted Therapy, and in press Serial Killing of

  34. Slide 34: Her2.TNK Anti-Glioma Activity in Mice

    Slide 34: Her2.TNK Anti-Glioma Activity in Mice

    Her2.TNK Tumor Intracranial xenografts Schoenfeld 34 homing in Demonstrate et LN-319 NSG al.ofMol CAR.TNKs mice glioblastoma Therapy, TumorinHoming press and Potent Anti-Glioma Activity in Mice

  35. Slide 35: Prospective CAR.TNK Target List

    Slide 35: Prospective CAR.TNK Target List

    Prospective (Initial Target EGFRviii.TNK EphA3.TNK L1CAM.TNK CSPG4.TNK BCMA.TNK ROR1.TNK PSMA PSCA.TNK PDL1.TNK CS1.TNK CD123.TNK CD19.TNK CD22.TNK CAR Lead Profit EGFRviii.TNK, Therapeutics, 35 company targets sharing Potential or List) Myeloma CAR.TNKs Myeloma, CLL, Prostate CLL, jointly Glioma, A

  36. Slide 36: Next Steps 2015-2016

    Slide 36: Next Steps 2015-2016

    Next2015 H1 H2 2016 36 Steps IND-enabling Generation for CAR.TNK studies, of CARs and evaluation Development IND submission, of stable CAR.TNK and initiation celloflines Phase 1 studies

  37. Slide 37: A Comprehensive Cancer Company

    Slide 37: A Comprehensive Cancer Company

    A Comprehensive Deep Novel Small Molecules Cytotoxics CYNVILOQ™ Cancer Targeted MYC TRAIL Bispecific (Partnership CYNVILOQ, 37 and inhibitor Biologics breakthrough Pain modulator Therapy Complementary Abs ADC Therapy Immunotherapy with CAR.TNK, Intractable Anti-VEGR2 PD1, Tumor-attacking Cell Conkwe

  38. Slide 38: Contact

    Slide 38: Contact

    Cancer607-4057 Next-Generation George CONTACT: Executive [email protected] (661) Therapeutics UyVice Henry President (858) Ji, Ph.D. 668-6923 and CCO [email protected] President and CEO

Source: SEC EDGAR · 8-K filed Jan 12, 2015

More decks from Sorrento Therapeutics, Inc.

All 41 Sorrento Therapeutics decks